Journal of Experimental & Clinical Cancer Research (Oct 2022)

HER3 in cancer: from the bench to the bedside

  • Lucía Gandullo-Sánchez,
  • Alberto Ocaña,
  • Atanasio Pandiella

DOI
https://doi.org/10.1186/s13046-022-02515-x
Journal volume & issue
Vol. 41, no. 1
pp. 1 – 26

Abstract

Read online

Abstract The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have therapeutic relevance. Furthermore, expression and activation of HER3 has been linked to resistance to drugs that target other HER receptors such as agents that act on EGFR or HER2. In addition, HER3 has been associated to resistance to some chemotherapeutic drugs. Because of those circumstances, efforts to develop and test agents targeting HER3 have been carried out. Two types of agents targeting HER3 have been developed. The most abundant are antibodies or engineered antibody derivatives that specifically recognize the extracellular region of HER3. In addition, the use of aptamers specifically interacting with HER3, vaccines or HER3-targeting siRNAs have also been developed. Here we discuss the state of the art of the preclinical and clinical development of drugs aimed at targeting HER3 with therapeutic purposes.

Keywords